Phase 1 Trial to Test ‘Off-the-shelf’ CAR T-cell Therapy CB-011 in 2023
Caribou Biosciences will soon start testing its new CAR T-cell therapy candidate, CB-011, in people with relapsed or refractory multiple myeloma. A Phase…
News
Dual FasTCAR T-Cell Therapy Effective Against Multiple Myeloma
GC012F, Gracell Biotechnologies’ investigational dual FastCAR T-cell therapy, was safe and highly effective at eradicating cancer cells in people with high-risk, newly diagnosed…
FDA Reviewing Motixafortide, Now Aphexda, for Stem Cell Transplants
The U.S. Food and Drug Administration (FDA) will review BioLineRx’s application to approve Aphexda, formerly known as motixafortide, as an add-on stem cell…
Real-world Study Supports Blenrep for Hard-to-treat RRMM
The efficacy and safety of Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma (RRMM) in a real-world setting is similar to what…
Tecvayli Approved in US for Heavily Pre-treated RRMM, With Conditions
Janssen’s Tecvayli (teclistamab) has been approved for certain adults with relapsed or refractory multiple myeloma in the U.S., but access is limited due…
1st Patient Dosed in Phase 1/2 Trial of Antibody Therapy ISB 1442
The first patient has been dosed in Ichnos Sciences’ Phase 1/2 clinical trial investigating ISB 1442, an experimental bi-specific antibody treatment for people with…
MCARH109, CAR T-cell Therapy for Advanced MM, Shows Potential
A new investigational CAR T-cell therapy, called MCARH109, demonstrated an ability to shrink or eliminate the amount of cancer in patients with relapsed or refractory…
M-Power Project for African Americans Now Includes New York
The International Myeloma Foundation’s (IMF) M-Power project, which seeks to improve disease outcomes for African Americans with multiple myeloma, has formed a partnership with…
OCEAN Trial Fails to Support Pepaxto for RRMM, FDA Panel Finds
An advisory panel to the U.S. Food and Drug Administration (FDA) has overwhelmingly decided that the Phase 3 OCEAN clinical trial did not provide sufficient…
Trial to Test Abecma in Patients With Poor Stem Cell Transplant Response
An upcoming clinical trial will evaluate the CAR T-cell therapy Abecma (idecabtagene vicleucel) in people newly diagnosed with multiple myeloma who had a…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML